Comparative Effects of Statins on the Kidney Function in Patients with Type 2 Diabetes

Hanai, Ko; Babazono, Tetsuya; Takemura, Shunsuke; Toyonaga, Aiko; Yoshida, Noriko; Uchigata, Yasuko

doi:10.5551/jat.26823

Cited by 7 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The bene cial effects of pravastatin on renal function reported in this study supports with the ndings of previous studies [11,12,22,23]. A post-hoc, large-scale RCT reported that patients with moderate CKD who received pravastatin therapy showed an increase in eGFR (+ 6.3%) [22].…”

Section: Discussionsupporting

confidence: 90%

“…These ndings suggest that use of pravastatin in patients with dyslipidemia and T2DM may provide better renal function than the use of other statins. A Japanese longitudinal cohort study reported that pravastatin outperformed rosuvastatin, atorvastatin, and pitavastatin in preserving renal function in patients with T2DM [12].…”

Section: Discussionmentioning

confidence: 99%

“…Pravastatin was reported to be associated with a 34% reduction in the rate of renal function loss in a post-hoc analysis of data from three randomized trials [11]. Moreover, a retrospective longitudinal cohort study on adult Japanese patients with type 2 diabetes mellitus (T2DM) reported that pravastatin showed superiority over other statins in preserving renal function [12]. however, this study was performed on a relatively small cohort at a single center.…”

Section: Introductionmentioning

confidence: 97%

See 2 more Smart Citations

Effect of pravastatin on renal function in patients with dyslipidemia and type 2 diabetes mellitus: A real-world observational study

Kim,

Hur,

Lee

et al. 2023

Preprint

View full text Add to dashboard Cite

Pravastatin can mitigate the progression of kidney disease; however, Asian data on its renal impact are lacking. This multicenter prospective observational study aimed to assess pravastatin’s effect on renal function in Korean patients with dyslipidemia and type 2 diabetes mellitus (T2DM) in real clinical practice. We enrolled 2,997 T2DM patients, who were followed up for 48 weeks post-pravastatin prescription. The effect of pravastatin on percent change in eGFR was assessed at weeks 12, 24, and 48 from baseline in patients (n = 2,604) with available estimated glomerular filtration rate (eGFR) values. We noted a significant improvement in eGFR, with mean percent changes of + 2.53 ± 26.65, + 2.56 ± 27.69, and + 2.96 ± 28.82% at the respective time points (all p < 0.01). Positive eGFR outcomes were observed in subgroups with baseline eGFR < 90 mL/min/1.73m², age ≥ 65 years, T2DM duration > 5 years, baseline glycated hemoglobin (HbA1c) ≥ 7%, and prior statin therapy. Concurrently, the pravastatin group exhibited improvements in the 24th week in lipid levels, and glucose levels, including fasting blood glucose and HbA1c. Our findings emphasize pravastatin’s potential to improve eGFR in Korean patients with dyslipidemia and T2DM, thus aiding in the attenuation of kidney disease progression.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Effect of pravastatin on renal function in patients with dyslipidemia and type 2 diabetes mellitus: A real-world observational study

Kim,

Hur,

Lee

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Some previous studies have reported that pravastatin improved kidney function in patients with moderate-to-severe kidney disease [12,13]. A post-hoc analysis of three RCTs conducted in the USA, UK, Scotland, and Australia reported that pravastatin was associated with a 34% decrease in the rate of kidney function loss.…”

Section: Statinsmentioning

confidence: 98%

Effect of Pravastatin on Kidney Function in Patients with Dyslipidemia and Type 2 Diabetes Mellitus: A Multicenter Prospective Observational Study

Kim,

Hur,

Lee

et al. 2024

Adv Ther

View full text Add to dashboard Cite

Introduction Several studies have reported that pravastatin can mitigate the progression of kidney disease, but limited evidence exists regarding its effects on kidney function in Asian patients. This multicenter prospective observational study aimed to assess the effect of pravastatin on kidney function in Korean patients with dyslipidemia and type 2 diabetes mellitus (T2DM) in clinical practice. Methods This 48-week prospective multicenter study included 2604 of 2997 eligible patients with dyslipidemia and T2DM who had available estimated glomerular filtration rate (eGFR) measurements. The primary endpoint was eGFR percent change at week 24 from baseline. We also assessed secondary endpoints, which included percent changes in eGFR at weeks 12 and 48 from baseline, as well as changes in eGFR, metabolic profiles (lipid and glycemic levels) at 12, 24, and 48 weeks from baseline, and safety. Results We noted a significant improvement in eGFR, with mean percent changes of 2.5%, 2.5%, and 3.0% at 12, 24, and 48 weeks, respectively (all adjusted p < 0.05). The eGFR percent changes significantly increased in subgroups with baseline eGFR 30–90 mL/min/1.73 m 2 , glycated hemoglobin (HbA1c) ≥ 7 at baseline, no hypertension history, T2DM duration > 5 years, or previous statin therapy. Lipid profiles were improved and remained stable throughout the study, and interestingly, fasting glucose and HbA1c were improved at 24 weeks. Conclusion Our findings suggest that pravastatin may have potential benefits for improving eGFR in Korean patients with dyslipidemia and T2DM. This could make it a preferable treatment option for patients with reduced kidney function. Trial Registration Number NCT05107063 submitted October 27, 2021. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-024-02862-5.

show abstract

“…In this sense, recent evidences indicate that not all statins display the same renal safety profile (progression of the CKD and/or effects on albumin/proteinuria) [28]. The selection of a statin in renal patients with nephropathy whether associated with diabetes or not [21,29], must guarantee its safe use. This does not seem to be always considered by prescribing practitioners [30].…”

Section: Sci Forschenmentioning

confidence: 99%

Recommendations for the Use of Statins in Patients with Diabetes Mellitus or Prediabetes. Conclusions of a Consensus Group

J¹,

Jf²,

Barrìos³

et al. 2017

J Dia Res Ther

View full text Add to dashboard Cite

The contribution of statins in the treatment of cardiovascular risk of lipid origin has been a determining factor in the reduction of morbimortality from cardiovascular diseases due to a decrease in risk. However, statins are not exempt from possible adverse effects. One of them is their capacity to cause disorders in the carbohydrate metabolism, increasing the risk of new-onset diabetes in patients treated with statins significantly, although the cardiovascular benefit of their use is always higher. Yet, especially in diabetic or pre-diabetic patients, the statin of choice may condition the safety in this area, given that the diabetogenic profile of the different molecules differ.In particular, the objectives of this study were to summarize the expert's opinion on whether all statins have a similar or different diabetogenic effect and to establish recommendations on the statin selection based on the patient characteristics.In order to ascertain the opinion of the experts (primary care physicians and other specialists with experience in the management of this type of patient) we conducted a Delphi study to evaluate the consensus rate on diverse aspects related to the diabetogenicity of different statins, and the factors that influence their choice.On the basis of the consensus agreements reached among practitioners of different specialities, and considering the availability of greater and better scientific evidence, this work groups together the recommendations to consider when selecting a statin in individuals with prediabetes or diagnosed diabetes. Such recommendations are grouped in relation with the patient, each individual's own carbohydrate metabolism, and the specific characteristics of every statin. These recommendations could facilitate the rational use of one statin or another in order diminish the diabetogenic potential shown by some of them.

show abstract

Comparative Effects of Statins on the Kidney Function in Patients with Type 2 Diabetes

Cited by 7 publications

References 36 publications

Effect of pravastatin on renal function in patients with dyslipidemia and type 2 diabetes mellitus: A real-world observational study

Effect of pravastatin on renal function in patients with dyslipidemia and type 2 diabetes mellitus: A real-world observational study

Effect of Pravastatin on Kidney Function in Patients with Dyslipidemia and Type 2 Diabetes Mellitus: A Multicenter Prospective Observational Study

Recommendations for the Use of Statins in Patients with Diabetes Mellitus or Prediabetes. Conclusions of a Consensus Group

Contact Info

Product

Resources

About